Buys
Open market- Shares
- +67,935
- Avg price
- $14.67
- Total value
- +$996,738
Behrenbruch Christian - MD & Group CEO, Director at Telix Pharmaceuticals Ltd
Issuer-level insider activity
- Role
- MD & Group CEO, Director
- Issuer ticker
- TLX on Nasdaq, TLPPF on OTC
- Entity type
- Individual
- Source filing history
- Open source filing history
Identity
Names, identifiers, and filing context for this profile.
1 identity field
Source evidence
Original filing metadata and source links for verification.
1 source field
Past-year transaction volume for Behrenbruch Christian in Telix Pharmaceuticals Ltd
Sells
Open market- Shares
- Avg price
- Total value
Net
Past year- Shares
- +67,935
- Share %
- 100%
- Total value
- +$996,738
Reported holdings for Behrenbruch Christian in Telix Pharmaceuticals Ltd
Form 4 holding
MD & Group CEO, Director
Telix Pharmaceuticals Ltd
- Security class
- Ordinary Shares
- Shares / value
- 20,742,935
- Estimated value
- $308,447,443
- Report date
- 29 Apr 2026
- Price
- $14.87
- Ownership
- Elk River Holdings Pty Ltd
Form 4 holding
MD & Group CEO, Director
Telix Pharmaceuticals Ltd
- Security class
- Ordinary Shares
- Shares / value
- 254,006
- Estimated value
- $1,910,125
- Report date
- 18 Mar 2026
- Price
- $7.52
- Ownership
- Direct
Form 4 holding
MD & Group CEO, Director
Telix Pharmaceuticals Ltd
- Security class
- American Depositary Receipts
- Shares / value
- 400,000
- Estimated value
- Report date
- 18 Mar 2026
- Price
- Ownership
- Direct
Transaction history for Behrenbruch Christian in Telix Pharmaceuticals Ltd
| Sym | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares after | Date | Ownership |
|---|
* marks a reported price that did not pass the local price check.